Randomised clinical trial: The safety and efficacy of AST-120 in non-constipating irritable bowel syndrome-a double-blind, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 8, 2011, Pages 868-877

  Tack, J F ^a   Miner, P B ^b   Fischer, L ^c   Harris, M S ^c,d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Oklahoma Foundation for Digestive Research   (United States)

^c MALLINCKRODT PHARMACEUTICALS   (United States)

^d GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AST 120; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON CONSTIPATING IRRITABLE BOWEL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BELGIUM; CARBON; CONSTIPATION; DIARRHEA; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; OXIDES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 80053193146     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04818.x     Document Type: Article

References (24)

1. Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-75. (Pubitemid 40813683)
2. Barbara G, Stanghellini V, De Giorgio R, Corinaldesi R,. Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 2006; 18: 6-17.
3. Spiller R,. Serotonergic modulating drugs for functional gastrointestinal diseases. Br J Clin Pharmacol 2002; 54: 11-20. (Pubitemid 36124749)
4. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006; 55: 1095-103. (Pubitemid 44085674)
5. Grundy D, Schemann M,. Enteric nervous system. Curr Opin Gastroenterol 2007; 23: 121-6. (Pubitemid 46192965)
6. Wood J,. Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis, and food allergies. Gut 2006; 55: 445-7.
7. Chadwick S, Chen Wm Shu D,. Acitivation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83.
8. Anderson K, Tomiyana S, Nitta T, et al. A novel, oral adsorbent, AST-120, specifically and irreversibly binds pro-inflammatory mediators in the gut in vitro and in vivo. Gut 2008; 57 (Suppl. 2): A75.
9. Anderson K, Fischer L,. Prevention of GI absorption of bacterial toxins: an in vitro evaluation of the potential for prophylactic use of a novel oral adsorbent. Gastroenterology 2008; 134 (Suppl. 1): A675.
10. Anderson K, Tomiyana S, Nitta T,. AST-120: a novel, engineeered carbon microsphere product for use in chronic inflammatory bowel disease and liver dysfunction. Gastroenterology 2008; 134 (Suppl. 1): A675.
11. Wilmer J, Anderson K, Proksch S, et al. Absence of Pharmacokinetic drug-drug interactions in healthy volunteers between AST-120, a novel oral adsorbent and concomitant medications: CiproXR (CFXR) and azathioprine (AZA). Gut 2008; 57 (Suppl. 2): A374.
12. Araki Y, Tsujikawa T, Andoh A, et al. Therapeutic effects of an oral adsorbent on acute dextran sulphate sodium-induced colitis and its recovery phase in rats, especially effects of elimination of bile acids in gut lumen. Digest Liver Dis 2000; 32: 691-8.
13. Tack J,. Antibiotic therapy for irritable bowel syndrome. N Engl J Med 2011; 364: 81-2.
14. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
15. Lewis SJ, Heaton KW,. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 920-4. (Pubitemid 27382038)
16. Francis CY, Morris J, Whorell PJ,. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997; 11: 395-402. (Pubitemid 27183522)
17. Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale: an updated literature review. J Psychosom Res 2002; 52: 69-77. (Pubitemid 34192886)
18. Patrick DL, Drossman DA, Frederick IO, et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 400-11. (Pubitemid 28124621)
19. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
20. Evans B, Clark W, Moore D, Whorwell PJ,. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; 1: CD003960.
21. 3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59. (Pubitemid 29445893)
22. Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome-results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2008; 29: 329-41.
23. Johnston JM, Kurtz CB, MacDougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a Phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-86.
24. Trentacosti AM, He R, Burke LB, Griebel D, Kennedy DL,. Evolution of clinical trials for irritable bowel syndrome: issues in end points and study design. Am J Gastroenterol 2010; 105: 731-5.